Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (52021)	3/10/2023 1:32:09 PM
From: Art Bechhoefer	Read Replies (2) \| Respond to of 52153

Although it is likely that ". . . companies that have lost the most are those furthest from earnings . . . ," there appear to be other factors that may determine share price. For example, VKTX probably won't get its NASH drug approved for another year, but it quadrupled in the past year, mainly in sympathy with MDGL, which has a similar drug that could be approved sooner. IONS, which has about 40 antisense drugs in various stages of development, may get two or three approved later this year, has about $2 billion cash for its development costs. Yet the stock has declined, despite good prospects for approval this year. Anybody know why? Art